Pulmonary hypertension in rheumatic diseases

被引:0
作者
Lang, IM [1 ]
Bonderman, D [1 ]
Skoro-Sajer, N [1 ]
Klepetko, W [1 ]
Kneussl, M [1 ]
机构
[1] Univ Vienna, Klin Innere Med 2, Klin Abt Kardiol, Allgemeines Krankenhaus Stadt Wien, A-1090 Vienna, Austria
来源
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2003年 / 62卷 / 01期
关键词
pulmonary hypertension; rheumatic disease; prostacyclin; prostacyclin analogues; endothelin receptor antagonists; calcium channel blockers; phosphodiesterase inhibitors; anticoagulation;
D O I
10.1007/s00393-003-0477-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pulmonary hypertension (PH) is a progressive disease of the pulmonary vasculature characterized by increased vascular resistance and pressure overload of the right ventricle. Histologically, PH lungs demonstrate medial hypertrophy of small pulmonary arteries and proliferation of endothelial cells resulting in plexiform lesions. Recent studies have identified mutations of the bone morphogenetic protein receptor 2 (BMPR2) gene and the activin-receptor-like kinase 1 (ALK1) gene, that affect the transforming growth factor beta (TGF-beta) receptor superfamily, a group of transmembrane signaling molecules with serine-threonine kinase activity that are involved in the regulation of cell growth. Several lines of evidence indicate that the development of PH is a multi-hit process, where one of the events is having a. gene mutation and another might be a circumstantial condition or other disease-modifying genes. It is unknown which mechanism that is critical in rheumatic diseases causes pulmonary vascular disease. PH is most frequently associated with systemic sclerosis (SS), systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD), however, it is still a rare manifestation of these disorders. For example, approximately 10% of SS cases manifest pulmonary vascular disease. In recent years symptomatic vasodilator therapies have been employed and have been able to improve exercise capacity and survival in these patients.
引用
收藏
页码:2 / 9
页数:8
相关论文
共 65 条
  • [1] ACUTE REVERSIBLE HYPOXEMIA IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    ABRAMSON, SB
    DOBRO, J
    EBERLE, MA
    BENTON, M
    REIBMAN, J
    EPSTEIN, H
    RAPOPORT, DM
    BELMONT, HM
    GOLDRING, RM
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 114 (11) : 941 - 947
  • [2] HEMODYNAMIC AND GAS-EXCHANGE RESPONSES TO INFUSION OF ACETYLCHOLINE AND INHALATION OF NITRIC-OXIDE IN PATIENTS WITH CHRONIC OBSTRUCTIVE LUNG-DISEASE AND PULMONARY-HYPERTENSION
    ADNOT, S
    KOUYOUMDJIAN, C
    DEFOUILLOY, C
    ANDRIVET, P
    SEDIAME, S
    HERIGAULT, R
    FRATACCI, MD
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 148 (02): : 310 - 316
  • [3] ASHERSON RA, 1990, J RHEUMATOL, V17, P1292
  • [4] Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial
    Badesch, DB
    Tapson, VF
    McGoon, MD
    Brundage, BH
    Rubin, LJ
    Wigley, FM
    Rich, S
    Barst, RJ
    Barrett, PS
    Kral, KM
    Jöbsis, MM
    Loyd, JE
    Murali, S
    Frost, A
    Girgis, R
    Bourge, RC
    Ralph, DD
    Elliott, CG
    Hill, NS
    Langleben, D
    Schilz, RJ
    McLaughlin, VV
    Robbins, IM
    Groves, BM
    Shapiro, S
    Medsger, TA
    Gaine, SP
    Horn, E
    Decker, JC
    Knobil, K
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) : 425 - +
  • [5] DISCRETE LUNG INVOLVEMENT IN SYSTEMIC LUPUS-ERYTHEMATOSUS - CT ASSESSMENT
    BANKIER, AA
    KIENER, HP
    WIESMAYR, MN
    FLEISCHMANN, D
    KONTRUS, M
    HEROLD, CJ
    GRANINGER, W
    HUBSCH, P
    [J]. RADIOLOGY, 1995, 196 (03) : 835 - 840
  • [6] Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension - Open-label pilot study
    Barst, RJ
    Rich, S
    Widlitz, A
    Horn, EM
    McLaughlin, V
    McFarlin, J
    [J]. CHEST, 2002, 121 (06) : 1860 - 1868
  • [7] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
    Barst, RJ
    Rubin, LJ
    Long, WA
    McGoon, MD
    Rich, S
    Badesch, DB
    Groves, BM
    Tapson, VF
    Bourge, RC
    Brundage, BH
    Koerner, SK
    Langleben, D
    Keller, CA
    Murali, S
    Uretsky, BF
    Clayton, LM
    Jobsis, MM
    Blackburn, SD
    Shortino, D
    Crow, JW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) : 296 - 301
  • [8] Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
    Channick, RN
    Simonneau, G
    Sitbon, O
    Robbins, IM
    Frost, A
    Tapson, VF
    Badesch, DB
    Roux, S
    Rainisio, M
    Bodin, F
    Rubin, LJ
    [J]. LANCET, 2001, 358 (9288) : 1119 - 1123
  • [9] CHANNICK RN, 1996, AM J RESP CRIT CARE, V153, pA86
  • [10] AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION
    CHRISTMAN, BW
    MCPHERSON, CD
    NEWMAN, JH
    KING, GA
    BERNARD, GR
    GROVES, BM
    LOYD, JE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (02) : 70 - 75